drugset
drugset / Trial / NCT02443740

Safety, Tolerability and Pharmacokinetics of BIIB118 (PF-05251749)

NCT02443740 ↗

Phase 1 Completed 32 enrolled Biogen
RandomizedCrossoverDouble-blindBasic science

Summary

This is a First in human (FIH) single ascending dose study to evaluate the safety, tolerability and pharmacokinetics (PKs) of BIIB118 following single oral doses in healthy human subjects

Timeline

Start
2015-05-31
Primary completion
2015-10-31
Completion
2015-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject BIIB118 Unknown 3 mg Oral
Subject BIIB118 Unknown 10 mg Oral
Subject BIIB118 Unknown 30 mg Oral
Subject BIIB118 Unknown 100 mg Oral
Subject BIIB118 Unknown 200 mg Oral
Subject BIIB118 Unknown 400 mg Oral
Subject BIIB118 Unknown 800 mg Oral

Indications

No indication recorded.